{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:33:19Z","timestamp":1765827199350},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine","award":["12F188139"],"award-info":[{"award-number":["12F188139"]}]},{"name":"Tokai University School of Medicine, Japan"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.diabres.2014.09.052","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T01:14:59Z","timestamp":1412817299000},"page":"451-457","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Predictors of response to liraglutide in Japanese type 2 diabetes"],"prefix":"10.1016","volume":"106","author":[{"given":"Masao","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsushige","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2014.09.052_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.diabres.2014.09.052_bib0010","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2014.09.052_bib0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose\u2013response relationships","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2014.09.052_bib0020","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2014.09.052_bib0025","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24h\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.09.052_bib0030","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.diabres.2014.09.052_bib0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/jdi.12111","article-title":"Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced \u03b2-cell function","volume":"4","author":"Usui","year":"2013","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2014.09.052_bib0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.2040-1124.2011.00168.x","article-title":"Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity","volume":"3","author":"Kozawa","year":"2012","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2014.09.052_bib0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdiacomp.2012.07.001","article-title":"Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes","volume":"27","author":"Iwao","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2014.09.052_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.2040-1124.2012.00242.x","article-title":"Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin","volume":"4","author":"Nambu","year":"2013","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2014.09.052_bib0055","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.diabres.2010.06.009","article-title":"Identification of metabolic syndrome using decision tree analysis","volume":"90","author":"Worachartcheewan","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.09.052_bib0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-10-0649","article-title":"Decision trees as a simple-to-use and reliable tool to identify individuals with impaired glucose metabolism or type 2 diabetes mellitus","volume":"163","author":"Hische","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabres.2014.09.052_bib0065","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1007\/s00125-006-0395-0","article-title":"Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling","volume":"49","author":"M\u00f6hlig","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2014.09.052_bib0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1185\/03007991003672551","article-title":"Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes","volume":"26","author":"Seino","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2014.09.052_bib0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.2040-1124.2011.00128.x","article-title":"Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes","volume":"2","author":"Kaku","year":"2011","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2014.09.052_bib0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","article-title":"Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes","volume":"12","author":"Kaku","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2014.09.052_bib0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.2040-1124.2011.00103.x","article-title":"Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial","volume":"2","author":"Seino","year":"2011","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.diabres.2014.09.052_bib0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714004525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714004525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:30:24Z","timestamp":1538159424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822714004525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0168822714004525"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2014.09.052","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of response to liraglutide in Japanese type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2014.09.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}